Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer - European Journal of Cancer
Enrolling Clinical Trials: Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer - Penn Medicine
Lynparza (olaparib) for the Treatment of BRCA-mutated Advanced Ovarian Cancer - Clinical Trials Arena
Platinum-Sensitive Recurrent Disease - PARPi in Ovarian Cancer - Module - PARPi in Ovarian Cancer - Oncology - Clinical Care Options
Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline BRCA mutations: OPINION Phase IIIb study design | Future Oncology
Olaparib Maintenance Reduces the Risk of Recurrence in Newly
Clinical Trials of PARP inhibitors in ovarian cancer | Download Table
Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evid | OTT
PAOLA-1 Phase 3 Trial – LYNPARZA® (olaparib) + Bevacizumab for Advanced Ovarian Cancer
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis - Gynecologic Oncology
Lynparza (olaparib) for the Treatment of BRCA-mutated Advanced Ovarian Cancer - Clinical Trials Arena
Blockbuster status competition intensifying for PARP inhibitors - Pharmaceutical Technology
Enrolling Clinical Trials: Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer - Penn Physician VideoLink
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial - The Lancet Oncology
3 Charts | Olaparib: A New Hope for BRCA Patients with Ovarian Cancer
Breakthrough from PAOLA1 GINECO/ENgOT-ov25 trial
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial - The Lancet Oncology
SOLO-1 Phase 3 Trial Demonstrates LYNPARZA® (olaparib) Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 Percent in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer | Business Wire
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy | British Journal of Cancer
PARP inhibitors: Choosing what to use in epithelial ovarian cancer
LYNPARZA® (olaparib) Efficacy for gBRCAm, HER2-negative Metastatic Breast Cancer
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial - ScienceDirect
Olaparib for Ovarian Cancer Clinical Trial | Power
Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis | Scientific Reports
